Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3
Open accessAbstract
Background Insulin-like growth factor 1 (IGF1) is an important determinant of muscle mass because it promotes growth and suppresses protein degradation. IGF1 is decreased in rheumatoid arthritis and juvenile idiopathic arthritis because its synthesis is inhibited by inflammation. In parallel, glucocorticoids induce IGF1 resistance and add to muscle degradation.Objective To investigate the influence of anti-tumour necrosis factor antibody treatment (anti-TNF) with adalimumab on levels of myoglobin (degradation marker) and IGF1 in patients with rheumatoid arthritis with and without prednisolone treatment.Methods Subcutaneous adalimumab was given to 32 patients with longstanding rheumatoid arthritis (16 with and 16 without prednisolone) in a longitudinal study. IGF1, IGF1 binding protein 1 (IGFBP-1), IGFBP-3, and myoglobin were measured by enzyme linked immunosorbent assay.Results Rheumatoid patients had normal serum myoglobin. Patients on prednisolone had higher myoglobin than patients not receiving prednisolone, indicating increased muscle degradation. On treatment with anti-TNF, myoglobin levels did not change in either patient group. Serum IGF1 was increased in patients with v without prednisolone, indicating IGF1 resistance (mean (SEM): 221 (23) v 122 (14) microg/l, p<0.001). Adalimumab treatment decreased the raised IGF1 levels in patients with prednisolone, so that after 12 weeks of treatment they reached the level of patients without prednisolone. Serum IGFBP-1 and IGFBP-3 did not differ in the two groups, and anti-TNF did not change these concentrations.Conclusions Anti-TNF antibody treatment over 12 weeks improved glucocorticoid induced IGF1 resistance without influencing myoglobin and IGF1 binding proteins. Thus, in rheumatoid patients on glucocorticoids with generally decreased muscle mass anti-TNF treatment with adalimumab has favourable effects.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IGF-1 resistance has been described in patients with rheumatoid arthritis.
“In addition, IGF-1 resistance was described in patients with RA [60]”
From Interaction of the endocrine system with inflammation: a function of energy and volume regulation (2014) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Venters, H., Tang, Q., Liu, Q., VanHoy, R. W., Dantzer, R., & Kelley, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9879 · Cited by 187 · see citing works
RetractedArnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753 · see citing works
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,742 · see citing works
Cachexia in rheumatoid arthritis
Walsmith, J., & Roubenoff, R. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00237-1 · Cited by 286 · see citing works
Tyler, J. A. (1989) · Biochemical Journal · doi:10.1042/bj2600543 · Cited by 277 · see citing works
Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N., & Drosos, A. A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.026534 · Cited by 254 · see citing works
Influence of Physical Activity on Insulin-Like Growth Factor-I in Healthy Younger and Older Men*
Poehlman, É. T., & Copeland, K. C. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-6-1468 · Cited by 239 · see citing works
Thissen, J., & Verniers, J. (1997) · Endocrinology · doi:10.1210/endo.138.3.4966 · Cited by 182 · see citing works
Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor
Fan, J., Char, D. J., Bagby, G. J., Gelato, M. C., & Lang, C. H. (1995) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1995.269.5.r1204 · Cited by 170 · see citing works
Eurenius, E., Opava, C. H., & The Para Study Group (2005) · Arthritis Care & Research · doi:10.1002/art.20924 · Cited by 146 · see citing works
Wolf, M., Böhm, S., Brand, M., & Kreymann, G. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350729 · Cited by 122 · see citing works
Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response
Munro, R., & Capell, H. A. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.5.326 · Cited by 114 · see citing works
Rall, L. C., Rosen, C. J., Dolnikowski, G. G., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390707 · Cited by 111 · see citing works
Regulation of Myostatin by Glucocorticoids After Thermal Injury
Lang, C. H., Silvis, C., Nystrom, G. J., & Frost, R. A. (2001) · The FASEB Journal · doi:10.1096/fj.00-0849fje · Cited by 105 · see citing works
Gayan‐Ramirez, G., Vanderhoydonc, F., Verhoeven, G., & Decramer, M. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9803021 · Cited by 102 · see citing works
Dexamethasone Inhibits Insulin-Like Growth Factor Signaling and Potentiates Myoblast Apoptosis
Singleton, J. R., Baker, B. L., & Thorburn, A. M. (2000) · Endocrinology · doi:10.1210/endo.141.8.7621 · Cited by 84 · see citing works
Effects of growth factors and cytokines on proteoglycan turnover in articular cartilage.
Hardingham, T., Bayliss, M. T., Rayan, V., et al. (1992) · PubMed · Cited by 72 · see citing works
Hollingdal, M., Juhl, C. B., Dall, R., Sturis, J., Veldhuis, J. D., Schmitz, O., & Pørksen, N. (2002) · Diabetologia · doi:10.1007/s125-002-8244-y · Cited by 67 · see citing works
Insulin-Like Growth Factor I: The Yin and Yang of Muscle Atrophy
Heszele, M. F. C., & Price, S. R. (2004) · Endocrinology · doi:10.1210/en.2004-1037 · Cited by 64 · see citing works
Lazarus, D. D., Moldawer, L. L., & Lowry, S. F. (1993) · PubMed · Cited by 62 · see citing works
Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia
Brink, M., Anwar, A., & Delafontaine, P. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00239-5 · Cited by 61 · see citing works
Lelbach, A., Scharf, J., & Ramadori, G. P. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00170-2 · Cited by 55 · see citing works
Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion
Rall, L. C., Walsmith, J., Snydman, L. K., Reichlin, S., Veldhuis, J. D., Kehayias, J. J., Abad, L. W., Lundgren, N., & Roubenoff, R. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10714 · Cited by 42 · see citing works
Fan, J., Li, Y. H., Bagby, G. J., et al. (1995) · Shock · doi:10.1097/00024382-199507000-00003 · Cited by 36 · see citing works
Soft tissue composition, quadriceps strength, bone quality and bone mass in rheumatoid arthritis.
Madsen, O. R., Egsmose, C., Hansen, B., et al. (1998) · PubMed · Cited by 35 · see citing works
Growth reconstitution in juvenile idiopathic arthritis treated with etanercept.
Schmeling, H., Seliger, E., & Horneff, G. (2004) · PubMed · Cited by 35 · see citing works
Pituitary growth hormone suppression withlow-dosage, long-acting corticoid administration
Stempfel, R. S., Sheikholislam, B. M., Lebovitz, H. E., Allen, E., & Franks, R. C. (1968) · The Journal of Pediatrics · doi:10.1016/s0022-3476(68)80188-x · Cited by 34 · see citing works
Dong, F. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00182-8 · Cited by 31 · see citing works
The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-I
Prummel, M. F., Wiersinga, W. M., Oosting, H., et al. (1996) · Journal of Endocrinological Investigation · doi:10.1007/bf03349028 · Cited by 28 · see citing works
Kind, K. L., Owens, J. A., Lok, F., et al. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.6.r1632 · Cited by 12 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- 28 Walsmith J , Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85 :89-99.
Cited by
Sorted by citations
Energy regulation and neuroendocrine–immune control in chronic inflammatory diseases
Straub, R. H., Cutolo, M., Buttgereit, F., & Pongratz, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02218.x · Cited by 382 · see citing works
Self-citationWong, S. C., Dobie, R., Altowati, M. A., Werther, G. A., Farquharson, C., & Ahmed, S. F. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1026 · Cited by 163 · see citing works
Modifying muscle mass – the endocrine perspective
Solomon, A. M., & Bouloux, P. M. G. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06837 · Cited by 156 · see citing works
State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training
Flynn, M. G., McFarlin, B. K., & Markofski, M. M. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607300283 · Cited by 154 · see citing works
Interaction of the endocrine system with inflammation: a function of energy and volume regulation
Straub, R. H. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4484 · Cited by 121 · see citing works
“Growth hormone via IGF-1 increases net whole-body protein synthesis and, thus, growth hormone has some anabolic effects [57], which might change during inflammatory illness because of growth hormone receptor resistance and loss of pulsatile growth hormone secretion [58-61].”
BackgroundSelf-citation
- Authors
- Sarzi-Puttini, P., Atzeni, F., Schölmerich, J., Cutolo, M., & Straub, R. H.
- Affiliations
- Luigi Sacco Hospital (IT)
- University Hospital Regensburg (DE)
- University of Genoa (IT)
- Corresponding author
- Straub, R H
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 65
- Issue
- 3
- Pages
- 301-305
- ISSN
- 0003-4967 (ISSN-L)
- PMC
- PMC1798065
- OpenAlex
- W2132511355
- Cited by
- 39
- References
- 30
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 1 · 2012: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- adalimumab, anti-TNF therapy, rheumatoid arthritis, insulin-like growth factor I, glucocorticoids, prednisolone, myoglobin, muscle mass, muscle degradation, juvenile idiopathic arthritis
- MeSH terms
- Adalimumab, Aged, Antibodies, Monoclonal, Arthritis, Rheumatoid, Drug Resistance, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Insulin-Like Growth Factor I, Longitudinal Studies, Male, Middle Aged, Muscular Diseases, Myoglobin, Prednisolone, Tumor Necrosis Factor-alpha, Interleukin-6, Antirheumatic Agents, Statistics, Nonparametric, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor Binding Protein 3, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
